Novel solvent-free fabrication of biodegradable poly-lactic-glycolic acid (PLGA) capsules for antibiotics and rhBMP-2 delivery.
Osteomyelitis has been one of the most common causes of post-operative problems and complications despite the advances in surgical techniques and the availability of newly developed antibiotics. Local antibiotic and growth factor delivery devices for treatment of various surgical infections have been studied recently, especially in the case of orthopedic infections. The report was to develop novel solvent-free biodegradable capsules for antibiotics and growth factors delivery. To fabricate a biodegradable capsule, polylactide-polyglycolide copolymers were pre-mixed with vancomycin. The mixture was then compression molded and sintered to form a cylinder with a cover of 8 mm in diameter. After the addition of 1 and 10 microg recombinant bone morphogenetic protein (rhBMP-2) into the core, an ultrasonic welder was used to seal the capsules. An elution method was employed to characterize the in vitro release characteristics of the antibiotics and the rhBMP-2 over a 30-day period. The HPLC analysis and the bacterial inhibition test showed that biodegradable capsules released high concentrations and activity of vancomycin (well above the minimum inhibition concentration) in vitro for the period of time needed to treat bone infection; i.e. 4-6 weeks. In addition, the results of ELISA and ALP tests also suggested that the capsules released active rhBMP-2 for up to 30 days. By adopting this novel technique, we will be able to fabricate biodegradable capsules of various medicines for long-term drug deliveries.
Liu
Shih-Jung
SJ
Department of Mechanical Engineering, Chang Gung University, Taiwan. shihjung@mail.cgu.edu.tw
Chi
Po-Sheng
PS
Lin
Song-Su
SS
Ueng
Steve Wen-Neng
SW
Chan
Err-Cheng
EC
Chen
Jan-Kan
JK
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000737:chemistry; D002214:Capsules / Q000138:chemical synthesis / Q000737:chemistry; D003692:Delayed-Action Preparations; D004797:Enzyme-Linked Immunosorbent Assay; D006016:Glycolates / Q000737:chemistry*; D006801:Humans; D019344:Lactic Acid; D008826:Microbial Sensitivity Tests; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry; D013211:Staphylococcus aureus / Q000187:drug effects; D013678:Technology, Pharmaceutical / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000737:chemistry; D014640:Vancomycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002214:Capsules; D003692:Delayed-Action Preparations; D006016:Glycolates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D014640:Vancomycin